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Introduction: Intravenous immunoglobulin is considered generally safe and is used widely as proven, and
sometimes empiric, treatment for an expanding list of autoimmune diseases. Thromboembolic complications
following intravenous immunoglobulin therapy are rare and there have been only five previous reports of stroke
occurring within 2 to 10 days of infusion. This is the first report of cerebral infarction occurring after a longer
latency of 3 weeks following intravenous immunoglobulin therapy in a patient presenting with Miller Fisher
syndrome.
Case presentation: A previously well, 44-year-old Sri Lankan man progressively developed ophthalmoplegia, facial
paralysis, ataxia and areflexia with neurophysiological and cerebrospinal fluid evidence consistent with the Miller
Fisher syndrome. He made an unremarkable recovery with intravenous immunoglobulin therapy (0.4g/kg/day for 5
days, total 180g), but developed a cerebral infarct with haemorrhagic transformation 25 days later. He was noted to
have a low blood pressure. Extensive investigations ruled out vasculopathic, embolic, thrombophilic and inflammatory
aetiologies. Circulating intravenous immunoglobulins combined with a low blood pressure was considered the most
probable cause of his stroke.
Conclusions: Cerebral infarction following intravenous immunoglobulin is thought to be secondary to hyperviscosity,
thromboemboli, vasculitis, or cerebral vasospasm and reported to occur after a short latency when the
immunoglobulin load is highest. Even though the immunoglobulin load is halved by 3 weeks, our case suggests that
that the predisposition to thromboembolism persists over a longer period and may result in vascular complications if
synergised with other vascular risk factors. It is recommended that intravenous immunoglobulin be infused at a rate of
not less than 8 hours per day and that factors predisposing to thromboembolism such as dehydration, immobilisation
and low blood pressure be avoided for the duration of at least two half-lives of immunoglobulin (6 weeks).
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ThrombosisIntroduction
Intravenous immunoglobulin (IVIg) is a preparation
fractionated from pooled human plasma, to contain pri-
marily immunoglobulin G (IgG). IVIg is increasingly
used as an effective treatment for an expanding list of
autoimmune diseases. Most adverse effects of IVIg are
mild and transient and IVIg is considered generally safe
[1]. Thromboembolic complications are recognised but* Correspondence: thashichang@gmail.com
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vascular risk factors [2]. There have been only five previ-
ous reports of cerebral infarction following IVIg therapy,
with reported latencies of 2 to 10 days following infusion
[3]. We report the occurrence of cerebral infarction after
a longer latency following IVIg therapy for Miller Fisher
syndrome (MFS) in a patient with no previous vascular
risk factors.
Case presentation
A previously well, 44-year-old Sri Lankan man presented
with perioral and acral paraesthesiae for 3 days associatedLtd. This is an Open Access article distributed under the terms of the Creative
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iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Fluid-attenuated inversion recovery magnetic resonance
imaging of brain showing an acute left parieto-occipital infarct
with haemorrhagic transformation and perilesional oedema.
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He was afebrile and there was no recent history of fever
or symptoms of infection. His general and neurological
examinations were normal. His blood counts, inflamma-
tory markers (erythrocyte sedimentation rate, C-reactive
protein), renal and liver function tests were normal. A
non-contrast-enhanced computed tomography scan of his
brain showed no abnormality. Two days after admission
to hospital, he developed a right lower motor neurone
(LMN) facial paralysis, left partial ptosis and diplopia. His
pupils were 3mm bilaterally and reacting to light. Muscle
power in his upper and lower limbs was 4+/5 and all deep
tendon reflexes were easily elicited. A day later, he devel-
oped bilateral LMN facial paralysis, bilateral complete ex-
ternal ophthalmoplegia with bilateral partial ptosis and
bilateral dilated pupils with no reaction to light. His
muscle power and tendon reflexes remained unchanged,
but he was ataxic. His vital lung capacity was 2000mL.
Contrast-enhanced magnetic resonance imaging and mag-
netic resonance angiogram (MRA) of his brain, and elec-
troencephalogram (EEG) were normal. Nerve conduction
studies showed focal segmental demyelination with sural
sparing. His cerebrospinal fluid (CSF) protein was elevated
at 207mg/dL, with no associated cells in the CSF. He was
treated with IVIg at 0.4g/kg/day (36g/day) for 5 days. Two
days later, he was noted to have global areflexia. He had
evidence of syndrome of inappropriate secretion of
antidiuretic hormone and required fluid restriction for
correction of electrolytes. His blood pressure showed
fluctuations from 180/100mmHg to 100/80mmHg and
he had a persistent tachycardia. From day 4 of IVIg, he
showed improvement in general health, eye movements,
facial weakness and incoordination. He was discharged
from hospital 11 days after admission. Since he had sev-
eral high blood pressure readings he was prescribed telmi-
sartan 40mg twice a day.
On review 3 weeks later, he appeared well with normal
eye and facial movements and normal coordination, but
complained of persistent headache of 2 days. Optic fundi
were normal. His muscle power was almost 5/5 but he had
global areflexia. He was noted to have had low blood pres-
sure recordings on home monitoring of 100 to 110/60 to
80mmHg and the telmisartan was reduced to once daily
with the proviso of stopping completely after further moni-
toring. On returning home after review, he had had difficulty
in expressing speech and had complained of worsening
headache. He was admitted to hospital the next day with
recurring secondary generalised seizures and was found to
have expressive aphasia and a right homonymous hemian-
opia. His blood pressure was 100/60mmHg. Brain imaging
showed evidence of a left parieto-occipital infarct with haem-
orrhagic transformation (Figure 1) and the EEG showed left
posterior sharp wave discharges. The MRA and venogram
were normal. An electrocardiogram, echocardiogram, bloodinvestigations including thrombophilia screening (activated
partial thromboplastin time, prothrombin time/international
normalised ratio, thrombin time, bleeding time/clotting time
and platelet count), plasma glucose and lipid profile, and
carotid duplex scan were normal. He was treated with intra-
venous midazolam, oral sodium valproate and clobazam for
seizures; the telmisartan was omitted and intravenous saline
was given to restore his blood pressure to 130/80mmHg. He
did not have further seizures but complained of increasing
headaches, which subsided with 2 days of mannitol and
intravenous dexamethasone. He was discharged from hos-
pital 3 days later and had a modified Rankin score of 2 on
discharge.Discussion
Cerebral infarction following IVIg is rare and thought to
be secondary to hyperviscosity, thromboemboli, vascu-
litis, or cerebral vasospasm [4]. Postmortem neuropatho-
logic analysis of IVIg-associated stroke in Guillain–Barré
syndrome (GBS) has shown evidence of intravascular
hypercoagulopathy and necrotising microangiopathy but
this finding is confounded by the presence of concurrent
myeloproliferative disease in the patient [5]. The postu-
lated mechanisms causing IVIg-related stroke are likely
to have a short latency since the IVIg load is highest
during the immediate post-infusion period. The previous
reports of IVIg-related stroke had latencies ranging from
2 to 10 days [3]. Of interest, our patient presented with
stroke 25 days following the completion of the IVIg
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the IVIg load in our patient at the time of stroke would
have been half of the initial loading dose of 180g and the
possibility of hyperviscosity, hypercoagulability or vaso-
spasms alone causing stroke seem less likely. However,
on a background of low blood pressure combined with
half of the loaded IVIg in circulation contributing to the
viscosity and the coagulability, it is probable that he had
a low-flow cerebral infarct. This is consistent with his
stroke occurring in a watershed territory (Figure 1). Our
patient had no other vascular risk factors and screening
for thrombophilia including antiphospholipid antibodies
was negative. A blood pressure of 100/70mmHg by itself
is unlikely to have caused a stroke in the absence of vas-
cular risk factors. Furthermore, early haemorrhagic
transformation of the infarct suggests thromboembolism
rather than pure low-flow as the mechanism of stroke [6].
MFS is characterised by the clinical triad of ophthal-
moplegia, ataxia, and areflexia, and is considered a vari-
ant form of GBS. In our patient areflexia was slow to
develop but subsequently occurred globally. Facial par-
alysis, although not characteristic, is a recognised feature
in 32% to 50% of patients with MFS [7,8]. A preceding
infection is not reported in up to a fifth of patients [8].
Clinically, MFS is mostly a self-limiting condition. How-
ever, cases progressing to respiratory failure requiring
mechanical ventilation and dysautonomia have been de-
scribed [8]. There are no randomised, double-blind,
placebo-controlled trials pertaining to the treatment.
The efficacy of plasmapheresis and IVIg has mostly been
described in case reports. However, it is reasonable to
consider treatment in cases with rapid progression of
disease.
Conclusions
Our case report highlights a rare but severe complica-
tion of IVIg therapy and the need for clinical discretion
in its use, particularly in self-limiting diseases such as
MFS. Furthermore, it is the first report of stroke occur-
ring 3 weeks after IVIg therapy suggesting that predis-
position to thromboembolism persists over a longer
period and may result in vascular complications if syner-
gised with other vascular risk factors. It is recommended
that IVIg be infused at a rate of not less than 8 hours
per day and that factors predisposing to thromboembol-
ism such as dehydration, immobilisation and low blood
pressure be avoided for the duration of at least two half-
lives of immunoglobulin (6 weeks).
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying im-
ages. A copy of the written consent is available for re-
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